Akebia Therapeutics
Clinical trials sponsored by Akebia Therapeutics, explained in plain language.
-
New drug hopes to slow kidney damage in FSGS patients
Disease control Recruiting nowThis study tests a new drug, praliciguat, for people with a kidney disease called focal segmental glomerulosclerosis (FSGS). About 60 adults will be randomly assigned to take either the drug or a placebo for 24 weeks, followed by 24 weeks where everyone gets the drug. The main go…
Phase: PHASE2 • Sponsor: Akebia Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug AKB-9090 takes first step: safety check in healthy volunteers
Knowledge-focused Recruiting nowThis early-stage study is testing a new drug called AKB-9090 for the first time in humans. The goal is to see if it is safe and how the body processes it. About 70 healthy adults will receive either the drug or a placebo, with doses given once or multiple times. This research is …
Phase: PHASE1 • Sponsor: Akebia Therapeutics • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC